NASDAQ:IART - Integra lifesciences Stock Price, Price Target & More

$60.02 +1.04 (+1.76 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$58.98
Today's Range$59.56 - $60.73
52-Week Range$41.51 - $60.73
Volume859,078 shs
Average Volume525,025 shs
Market Capitalization$4.32 billion
P/E Ratio30.80
Dividend YieldN/A
Beta0.65

About Integra lifesciences (NASDAQ:IART)

Integra lifesciences logoIntegra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500

Debt

Debt-to-Equity Ratio1.85%
Current Ratio2.36%
Quick Ratio1.51%

Price-To-Earnings

Trailing P/E Ratio30.80
Forward P/E Ratio25.76
P/E Growth1.69

Sales & Book Value

Annual Sales$1.19 billion
Price / Sales3.99
Cash Flow$3.4278 per share
Price / Cash17.51
Book Value$12.26 per share
Price / Book4.90

Profitability

EPS (Most Recent Fiscal Year)$1.94
Net Income$64.74 million
Net Margins5.45%
Return on Equity16.94%
Return on Assets6.27%

Miscellaneous

Employees4,400
Outstanding Shares78,960,000

How to Become a New Pot Stock Millionaire

Integra lifesciences (NASDAQ:IART) Frequently Asked Questions

What is Integra lifesciences' stock symbol?

Integra lifesciences trades on the NASDAQ under the ticker symbol "IART."

When did Integra lifesciences' stock split? How did Integra lifesciences' stock split work?

Integra lifesciences's stock split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were payable to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra lifesciences stock prior to the split would have 200 shares after the split.

How were Integra lifesciences' earnings last quarter?

Integra lifesciences (NASDAQ:IART) issued its earnings results on Wednesday, April, 25th. The life sciences company reported $0.58 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.49 by $0.09. The life sciences company earned $357.10 million during the quarter, compared to analyst estimates of $349.15 million. Integra lifesciences had a return on equity of 16.94% and a net margin of 5.45%. The company's quarterly revenue was up 38.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.39 EPS. View Integra lifesciences' Earnings History.

When is Integra lifesciences' next earnings date?

Integra lifesciences is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Integra lifesciences.

What guidance has Integra lifesciences issued on next quarter's earnings?

Integra lifesciences updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $2.34-2.42 for the period, compared to the Thomson Reuters consensus estimate of $2.33. The company issued revenue guidance of $1.47-1.49 billion, compared to the consensus revenue estimate of $1.48 billion.

What price target have analysts set for IART?

14 brokers have issued 1 year target prices for Integra lifesciences' shares. Their forecasts range from $50.00 to $70.00. On average, they anticipate Integra lifesciences' stock price to reach $57.4167 in the next twelve months. View Analyst Ratings for Integra lifesciences.

What are Wall Street analysts saying about Integra lifesciences stock?

Here are some recent quotes from research analysts about Integra lifesciences stock:
  • 1. Cantor Fitzgerald analysts commented, "IART announced preliminary 4Q revenue of $365MM, beating FactSet consensus by $13MM. The beat was driven by better than expected contribution from the Codman and DermaScience acquisitions." (1/5/2018)
  • 2. According to Zacks Investment Research, "Integra LifeSciences' contracting adjusted operating margin and adjusted gross margin have been causing troubles for the company of late. Also the company’s decision to sell its certain neurosurgery assets to Natus Medical may hamper its business in near term. However, the strong year-over-year increase in revenues on the back of strong growth within Orthopedics and Tissue Technologies segment buoys optimism. Raised full-year revenue guidance is indicative of this bullish trend to remain. We are happy with the fact that, the company is efficiently executing its growth plan through an efficient management team. However, the slashed full-year adjusted earnings range remains a concern. Overall, over the past year, Integra Lifesciences has been trading above the broader industry." (12/26/2017)

Who are some of Integra lifesciences' key competitors?

Who are Integra lifesciences' key executives?

Integra lifesciences' management team includes the folowing people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 53)
  • Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 75)
  • Mr. Glenn G. Coleman, Corp. VP & CFO (Age 50)
  • Mr. Richard D. Gorelick, Corp. VP of Admin., Gen. Counsel & Sec. (Age 57)
  • Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 55)

Has Integra lifesciences been receiving favorable news coverage?

News coverage about IART stock has been trending somewhat positive on Thursday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Integra lifesciences earned a daily sentiment score of 0.11 on Accern's scale. They also assigned news headlines about the life sciences company an impact score of 46.42 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Integra lifesciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Integra lifesciences' stock price today?

One share of IART stock can currently be purchased for approximately $60.02.

How big of a company is Integra lifesciences?

Integra lifesciences has a market capitalization of $4.32 billion and generates $1.19 billion in revenue each year. The life sciences company earns $64.74 million in net income (profit) each year or $1.94 on an earnings per share basis. Integra lifesciences employs 4,400 workers across the globe.

How can I contact Integra lifesciences?

Integra lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]


MarketBeat Community Rating for Integra lifesciences (IART)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  301 (Vote Outperform)
Underperform Votes:  316 (Vote Underperform)
Total Votes:  617
MarketBeat's community ratings are surveys of what our community members think about Integra lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Integra lifesciences (NASDAQ:IART) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
14 Wall Street analysts have issued ratings and price targets for Integra lifesciences in the last 12 months. Their average twelve-month price target is $57.4167, suggesting that the stock has a possible downside of 4.34%. The high price target for IART is $70.00 and the low price target for IART is $50.00. There are currently 10 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.292.272.272.73
Ratings Breakdown: 0 Sell Rating(s)
10 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $57.4167$54.8889$52.4444$53.2727
Price Target Upside: 4.34% downside3.40% downside6.66% upside12.01% upside

Integra lifesciences (NASDAQ:IART) Consensus Price Target History

Price Target History for Integra lifesciences (NASDAQ:IART)

Integra lifesciences (NASDAQ:IART) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/26/2018Morgan StanleyBoost Price TargetEqual Weight -> Equal Weight$53.00 -> $58.00LowView Rating Details
4/26/2018JPMorgan ChaseBoost Price TargetNeutral -> Neutral$55.00 -> $57.00LowView Rating Details
4/26/2018CitigroupReiterated RatingOutperform$60.00 -> $70.00LowView Rating Details
4/25/2018OppenheimerReiterated RatingBuyLowView Rating Details
4/5/2018BTIG ResearchInitiated CoverageNeutral$56.00LowView Rating Details
3/1/2018Jefferies GroupReiterated RatingBuy$63.00LowView Rating Details
2/28/2018JMP SecuritiesBoost Price TargetMarket Outperform -> Market Outperform$57.00 -> $60.00MediumView Rating Details
1/9/2018BarclaysReiterated RatingHold$53.00LowView Rating Details
1/5/2018Cantor FitzgeraldReiterated RatingNeutral -> Neutral$52.00MediumView Rating Details
1/2/2018UBSDowngradeMarket PerformLowView Rating Details
1/2/2018Raymond JamesReiterated RatingOutperform -> Market Perform$55.00MediumView Rating Details
1/2/2018Bank of AmericaDowngradeBuy -> NeutralHighView Rating Details
11/9/2017Royal Bank of CanadaReiterated RatingSector Perform -> Sector Perform$48.00 -> $50.00N/AView Rating Details
10/29/2017Wells FargoDowngradeOutperform -> Market PerformN/AView Rating Details
3/22/2017Piper JaffrayReiterated RatingOverweight$47.00LowView Rating Details
10/28/2016Lake Street CapitalUpgradeHold -> Buy$46.00N/AView Rating Details
9/23/2016ArgusBoost Price TargetBuy$45.00 -> $52.50N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Integra lifesciences (NASDAQ:IART) Earnings History and Estimates Chart

Earnings by Quarter for Integra lifesciences (NASDAQ:IART)

Integra lifesciences (NASDAQ:IART) Earnings Estimates

2018 EPS Consensus Estimate: $2.32
2019 EPS Consensus Estimate: $2.67
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$0.45$0.51$0.49
Q2 20184$0.55$0.58$0.56
Q3 20184$0.57$0.60$0.58
Q4 20184$0.63$0.74$0.69
Q1 20192$0.56$0.59$0.58
Q2 20192$0.63$0.68$0.66
Q3 20192$0.67$0.69$0.68
Q4 20192$0.75$0.77$0.76

Integra lifesciences (NASDAQ IART) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018        
4/25/2018Q1 2018$0.49$0.58$349.15 million$357.10 millionViewN/AView Earnings Details
2/27/2018Q4 2017$0.56$0.64$362.64 million$368.60 millionViewN/AView Earnings Details
10/26/2017Q3 2017$0.47$0.45$286.00 million$278.83 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.45$0.45$283.58 million$282.16 millionViewN/AView Earnings Details
4/26/2017Q1 17$0.40$0.39$254.19 million$258.60 millionViewN/AView Earnings Details
2/23/2017Q4 2016$0.52$0.52$257.27 million$255.70 millionViewN/AView Earnings Details
10/27/2016Q3$0.89$0.93$249.30 million$250.30 millionViewListenView Earnings Details
7/28/2016Q216$0.76$0.79$243.17 million$249.30 millionViewListenView Earnings Details
4/27/2016Q116$0.73$0.74$230.66 million$236.80 millionViewListenView Earnings Details
2/25/2016Q4$0.86$0.87$241.11 million$241.20 millionViewListenView Earnings Details
11/3/2015Q315$0.74$0.75$224.08 million$226.40 millionViewListenView Earnings Details
7/30/2015Q215$0.73$0.79$239.91 million$244.10 millionViewListenView Earnings Details
4/30/2015Q115$0.63$0.76$229.69 million$233.70 millionViewN/AView Earnings Details
2/24/2015Q414$0.89$0.94$244.39 million$252.20 millionViewListenView Earnings Details
11/3/2014Q314$0.74$0.76$233.50 million$229.70 millionViewListenView Earnings Details
8/5/2014Q214$0.63$0.68$229.32 million$231.40 millionViewN/AView Earnings Details
5/1/2014Q114$0.58$0.57$213.30 million$215.00 millionViewN/AView Earnings Details
2/25/2014Q413$0.81$0.78$223.37 million$220.80 millionViewN/AView Earnings Details
10/28/2013Q313$0.70$0.72$214.05 million$213.20 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.55$0.60$207.30 million$205.50 millionViewN/AView Earnings Details
5/2/2013Q1 2013$0.37$0.39$195.20 million$196.70 millionViewN/AView Earnings Details
2/21/2013Q4 2012$0.76$0.78$215.90 million$214.40 millionViewN/AView Earnings Details
10/24/2012$0.77$0.85ViewN/AView Earnings Details
7/26/2012$0.69$0.74ViewN/AView Earnings Details
4/25/2012$0.60$0.71ViewN/AView Earnings Details
2/23/2012$0.55$0.72ViewN/AView Earnings Details
10/31/2011$0.77$0.77ViewN/AView Earnings Details
7/28/2011$0.61$0.70ViewN/AView Earnings Details
4/28/2011$0.66$0.66ViewN/AView Earnings Details
2/24/2011$0.73$0.80ViewN/AView Earnings Details
10/28/2010Q3 2010$0.33$0.33ViewN/AView Earnings Details
7/29/2010Q2 2010$0.32$0.34ViewN/AView Earnings Details
5/3/2010Q1 2010$0.28$0.31ViewN/AView Earnings Details
3/1/2010Q4 2009$0.29$0.30ViewN/AView Earnings Details
11/4/2009Q3 2009$0.26$0.27ViewN/AView Earnings Details
8/6/2009Q2 2009$0.25$0.26ViewN/AView Earnings Details
5/6/2009Q1 2009$0.23$0.23ViewN/AView Earnings Details
3/2/2009Q4 2008$0.28$0.27ViewN/AView Earnings Details
11/7/2008Q3 2008$0.23$0.24ViewN/AView Earnings Details
8/11/2008Q2 2008$0.23$0.25ViewN/AView Earnings Details
6/4/2008Q1 2008$0.20$0.25ViewN/AView Earnings Details
5/17/2008Q4 2007$0.27ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Integra lifesciences (NASDAQ:IART) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Integra lifesciences (NASDAQ IART) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 90.36%
Insider Trading History for Integra lifesciences (NASDAQ:IART)
Institutional Ownership by Quarter for Integra lifesciences (NASDAQ:IART)

Integra lifesciences (NASDAQ IART) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2018Glenn ColemanVPSell8,769$56.10$491,940.90View SEC Filing  
3/9/2018Joseph VinhaisVPSell6,800$54.13$368,084.00View SEC Filing  
3/8/2018Richard E CarusoMajor ShareholderSell32,880$53.68$1,764,998.40View SEC Filing  
3/5/2018Christian S SchadeDirectorSell15,658$52.88$827,995.0475,262View SEC Filing  
2/26/2018Keith BradleyDirectorSell15,658$55.00$861,190.0037,074View SEC Filing  
11/20/2017Jeffrey MosebrookInsiderSell160$47.41$7,585.60View SEC Filing  
11/14/2017Richard D GorelickVPSell1,500$47.19$70,785.0021,665View SEC Filing  
10/31/2017Barbara B HillDirectorBuy10,768$46.66$502,434.8855,540View SEC Filing  
8/4/2017Donald E Morel JrDirectorBuy10,000$49.25$492,500.0029,612View SEC Filing  
8/3/2017Donald E Morel JrDirectorBuy2,500$49.29$123,225.0029,612View SEC Filing  
8/1/2017Barbara B HillDirectorBuy5,050$49.33$249,116.5044,772View SEC Filing  
5/25/2017Stuart EssigDirectorSell135,000$49.90$6,736,500.002,077,475View SEC Filing  
5/23/2017Stuart EssigDirectorSell140,000$48.01$6,721,400.00View SEC Filing  
5/4/2017Glenn ColemanVPSell13,865$45.91$636,542.1518,519View SEC Filing  
5/4/2017James M SullivanDirectorSell15,658$45.89$718,545.6270,154View SEC Filing  
11/8/2016Peter J ArduiniCEOSell24,009$79.51$1,908,955.5925,593View SEC Filing  
8/23/2016Raymond G MurphyDirectorSell2,600$86.64$225,264.0033,047View SEC Filing  
8/9/2016Peter J ArduiniCEOSell24,009$84.52$2,029,240.6829,602View SEC Filing  
8/4/2016Raymond G MurphyDirectorSell2,610$84.83$221,406.3033,057View SEC Filing  
8/1/2016Richard D GorelickVPSell4,000$84.60$338,400.009,702View SEC Filing  
5/9/2016Joseph VinhaisVPSell972$73.36$71,305.924,311View SEC Filing  
5/4/2016Glenn ColemanCFOSell3,563$70.62$251,619.0612,263View SEC Filing  
5/3/2016Christian S SchadeDirectorSell7,829$70.42$551,318.1818,550View SEC Filing  
5/2/2016Daniel L ReuversVPSell1,000$71.43$71,430.009,747View SEC Filing  
4/29/2016Richard D GorelickVPSell4,000$70.72$282,880.0013,702View SEC Filing  
4/27/2016Stuart EssigDirectorSell104,390$70.15$7,322,958.501,064,709View SEC Filing  
4/6/2016Stuart EssigDirectorSell21,100$66.19$1,396,609.00981,419View SEC Filing  
4/5/2016Stuart EssigDirectorSell83,290$66.68$5,553,777.201,002,469View SEC Filing  
4/4/2016Stuart EssigDirectorSell42,150$67.26$2,835,009.001,002,469View SEC Filing  
5/7/2015Stuart EssigDirectorSell75,000$64.32$4,824,000.00View SEC Filing  
5/6/2015Stuart EssigDirectorSell125,000$64.83$8,103,750.00View SEC Filing  
1/2/2015Judith OgradyVPSell3,500$53.33$186,655.00View SEC Filing  
10/28/2014Stuart EssigDirectorSell147,098$49.58$7,293,118.84View SEC Filing  
10/27/2014Stuart EssigDirectorSell41,268$49.56$2,045,242.08View SEC Filing  
9/2/2014Judith OgradyVPSell2,500$49.82$124,550.00View SEC Filing  
8/27/2014Richard D GorelickVPSell7,000$50.03$350,210.00View SEC Filing  
8/25/2014John B Henneman IIICAOSell20,000$50.12$1,002,400.00View SEC Filing  
8/22/2014Deborah A LeonettiVPSell1,000$50.96$50,960.00View SEC Filing  
8/8/2014Brian LarkinVPSell1,947$48.28$94,001.16View SEC Filing  
7/30/2014Stuart EssigDirectorSell50,800$47.76$2,426,208.00View SEC Filing  
7/23/2014Stuart EssigDirectorSell27,819$47.80$1,329,748.20View SEC Filing  
7/1/2014Judith OgradyVPSell2,500$47.54$118,850.00View SEC Filing  
6/23/2014Stuart EssigDirectorSell21,381$47.76$1,021,156.56View SEC Filing  
4/3/2014Stuart EssigDirectorSell6,344$46.01$291,887.441,051,166View SEC Filing  
4/2/2014Stuart EssigDirectorSell76,177$46.05$3,507,950.851,057,510View SEC Filing  
3/31/2014Stuart EssigDirectorSell17,479$46.05$804,907.951,133,687View SEC Filing  
3/10/2014Deborah LeonettiVPSell7,563$49.22$372,250.869,955View SEC Filing  
3/4/2014Richard GorelickVPSell2,000$47.98$95,960.0018,296View SEC Filing  
2/28/2014Christian SchadeDirectorSell7,500$47.06$352,950.0011,902View SEC Filing  
2/27/2014Brian LarkinVPSell3,265$46.15$150,679.7510,256View SEC Filing  
2/27/2014John Henneman IIICFOSell5,000$46.07$230,350.0063,611View SEC Filing  
1/16/2014Stuart EssigDirectorSell8,037$49.59$398,554.831,151,166View SEC Filing  
1/14/2014Stuart EssigDirectorSell10,600$49.50$524,700.001,151,166View SEC Filing  
1/13/2014Stuart EssigDirectorSell99,032$49.51$4,903,074.321,151,166View SEC Filing  
1/9/2014Stuart EssigDirectorSell114,431$49.58$5,673,488.981,151,166View SEC Filing  
8/30/2013Richard GorelickVPSell3,000$40.79$122,370.0020,296View SEC Filing  
8/23/2013Deborah LeonettiVPSell8,906$41.68$371,202.0817,518View SEC Filing  
8/19/2013Brian LarkinVPSell7,490$41.90$313,831.0013,521View SEC Filing  
8/19/2013John Henneman IIICFOSell30,000$42.08$1,262,400.0072,669View SEC Filing  
8/1/2013Judith OgradyVPSell1,000$39.50$39,500.00View SEC Filing  
7/30/2013Judith OgradyVPSell2,000$38.50$77,000.00View SEC Filing  
5/31/2013Jerry E CorbinVPSell1,876$38.07$71,419.32View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Integra lifesciences (NASDAQ IART) News Headlines

Source:
DateHeadline
Integra LifeSciences (IART) Tops on Q1 Earnings, 18 View UpIntegra LifeSciences (IART) Tops on Q1 Earnings, '18 View Up
www.msn.com - April 26 at 5:04 PM
Edited Transcript of IART earnings conference call or presentation 25-Apr-18 12:30pm GMTEdited Transcript of IART earnings conference call or presentation 25-Apr-18 12:30pm GMT
finance.yahoo.com - April 26 at 5:04 PM
Integra LifeSciences to Present at Healthcare Conference in May 2018Integra LifeSciences to Present at Healthcare Conference in May 2018
finance.yahoo.com - April 26 at 5:04 PM
Morgan Stanley Raises Integra lifesciences (IART) Price Target to $58.00Morgan Stanley Raises Integra lifesciences (IART) Price Target to $58.00
www.americanbankingnews.com - April 26 at 12:35 PM
Integra lifesciences (IART) Receives "Outperform" Rating from CitigroupIntegra lifesciences (IART) Receives "Outperform" Rating from Citigroup
www.americanbankingnews.com - April 26 at 10:33 AM
JPMorgan Chase Raises Integra lifesciences (IART) Price Target to $57.00JPMorgan Chase Raises Integra lifesciences (IART) Price Target to $57.00
www.americanbankingnews.com - April 26 at 9:00 AM
Oppenheimer Reiterates Buy Rating for Integra lifesciences (IART)Oppenheimer Reiterates Buy Rating for Integra lifesciences (IART)
www.americanbankingnews.com - April 26 at 8:00 AM
Integra LifeSciences Holdings (IART) Q1 2018 Results - Earnings Call TranscriptIntegra LifeSciences Holdings (IART) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 25 at 5:16 PM
Integra lifesciences (IART) Announces Quarterly  Earnings ResultsIntegra lifesciences (IART) Announces Quarterly Earnings Results
www.americanbankingnews.com - April 25 at 1:40 PM
Integra lifesciences (IART) Releases FY18 Earnings GuidanceIntegra lifesciences (IART) Releases FY18 Earnings Guidance
www.americanbankingnews.com - April 25 at 9:58 AM
Integra LifeSciences Reports First Quarter 2018 Financial ResultsIntegra LifeSciences Reports First Quarter 2018 Financial Results
finance.yahoo.com - April 25 at 8:35 AM
Integra: 1Q Earnings SnapshotIntegra: 1Q Earnings Snapshot
finance.yahoo.com - April 25 at 8:35 AM
Integra LifeSciences Q1 Profit Rises; Lifts 2018 OutlookIntegra LifeSciences Q1 Profit Rises; Lifts 2018 Outlook
www.nasdaq.com - April 25 at 8:35 AM
Integra LifeSciences Holdings beats by $0.09, beats on revenueIntegra LifeSciences Holdings beats by $0.09, beats on revenue
seekingalpha.com - April 25 at 8:35 AM
Integra LifeSciences (IART) Tops Q1 EPS by 9c, Beats on Revenues; Boosts FY18 EPS/Revenue OutlookIntegra LifeSciences (IART) Tops Q1 EPS by 9c, Beats on Revenues; Boosts FY18 EPS/Revenue Outlook
www.streetinsider.com - April 25 at 8:35 AM
Integra lifesciences (IART) "Buy" Rating Reiterated at UBSIntegra lifesciences' (IART) "Buy" Rating Reiterated at UBS
www.americanbankingnews.com - April 20 at 10:18 PM
Bio-Rad Laboratories (BIO) versus Integra lifesciences (IART) Financial SurveyBio-Rad Laboratories (BIO) versus Integra lifesciences (IART) Financial Survey
www.americanbankingnews.com - April 19 at 11:29 AM
Integra lifesciences (IART) Given Average Rating of "Hold" by AnalystsIntegra lifesciences (IART) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 18 at 1:35 PM
Integra lifesciences (IART) to Release Earnings on WednesdayIntegra lifesciences (IART) to Release Earnings on Wednesday
www.americanbankingnews.com - April 18 at 4:20 AM
Zacks: Analysts Anticipate Integra lifesciences (IART) Will Post Quarterly Sales of $349.61 MillionZacks: Analysts Anticipate Integra lifesciences (IART) Will Post Quarterly Sales of $349.61 Million
www.americanbankingnews.com - April 17 at 5:01 AM
Integra lifesciences (IART) Lowered to "Hold" at BidaskClubIntegra lifesciences (IART) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - April 16 at 6:30 PM
Integra lifesciences (IART) Rating Reiterated by OppenheimerIntegra lifesciences (IART) Rating Reiterated by Oppenheimer
www.americanbankingnews.com - April 15 at 8:22 PM
Integra lifesciences (IART) Given a $65.00 Price Target by Cantor Fitzgerald AnalystsIntegra lifesciences (IART) Given a $65.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - April 15 at 5:39 PM
Integra lifesciences (IART) Raised to "Hold" at Zacks Investment ResearchIntegra lifesciences (IART) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 15 at 2:53 PM
Integra lifesciences (IART) Given New $55.00 Price Target at Raymond James FinancialIntegra lifesciences (IART) Given New $55.00 Price Target at Raymond James Financial
www.americanbankingnews.com - April 15 at 12:00 PM
 Analysts Anticipate Integra lifesciences (IART) Will Announce Earnings of $0.49 Per Share Analysts Anticipate Integra lifesciences (IART) Will Announce Earnings of $0.49 Per Share
www.americanbankingnews.com - April 15 at 1:17 AM
IART Crosses Above Average Analyst TargetIART Crosses Above Average Analyst Target
www.nasdaq.com - April 13 at 5:15 PM
Integra LifeSciences to Host First Quarter 2018 Earnings Results Conference ...Integra LifeSciences to Host First Quarter 2018 Earnings Results Conference ...
globenewswire.com - April 12 at 9:12 AM
Integra LifeSciences to Host First Quarter 2018 Earnings Results Conference Call on April 25, 2018Integra LifeSciences to Host First Quarter 2018 Earnings Results Conference Call on April 25, 2018
finance.yahoo.com - April 11 at 5:11 PM
Integra lifesciences (IART) Price Target Raised to $55.00 at JPMorgan ChaseIntegra lifesciences (IART) Price Target Raised to $55.00 at JPMorgan Chase
www.americanbankingnews.com - April 11 at 9:23 AM
Integra lifesciences (IART) Now Covered by Analysts at BTIG ResearchIntegra lifesciences (IART) Now Covered by Analysts at BTIG Research
www.americanbankingnews.com - April 5 at 11:32 AM
Integra lifesciences (IART) Rating Reiterated by UBSIntegra lifesciences (IART) Rating Reiterated by UBS
www.americanbankingnews.com - April 2 at 6:59 PM
Integra lifesciences (IART) Receives "Sector Perform" Rating from Royal Bank of CanadaIntegra lifesciences (IART) Receives "Sector Perform" Rating from Royal Bank of Canada
www.americanbankingnews.com - March 31 at 6:06 PM
Integra lifesciences (IART) Downgraded to Market Perform at UBSIntegra lifesciences (IART) Downgraded to Market Perform at UBS
www.americanbankingnews.com - March 31 at 12:16 PM
Integra lifesciences (IART) Downgraded by Bank of AmericaIntegra lifesciences (IART) Downgraded by Bank of America
www.americanbankingnews.com - March 31 at 11:54 AM
$349.61 Million in Sales Expected for Integra lifesciences (IART) This Quarter$349.61 Million in Sales Expected for Integra lifesciences (IART) This Quarter
www.americanbankingnews.com - March 31 at 4:36 AM
Integra lifesciences (IART) PT Set at $58.00 by OppenheimerIntegra lifesciences (IART) PT Set at $58.00 by Oppenheimer
www.americanbankingnews.com - March 30 at 1:49 PM
Why Is Integra LifeSciences (IART) Up 3.6% Since Its Last Earnings Report?Why Is Integra LifeSciences (IART) Up 3.6% Since Its Last Earnings Report?
finance.yahoo.com - March 29 at 5:13 PM
Integra lifesciences (IART) Earns Buy Rating from OppenheimerIntegra lifesciences (IART) Earns Buy Rating from Oppenheimer
www.americanbankingnews.com - March 28 at 9:16 PM
Integra Lifesciences (IART) Upgraded by BidaskClub to "Sell"Integra Lifesciences (IART) Upgraded by BidaskClub to "Sell"
www.americanbankingnews.com - March 25 at 2:34 PM
Integra Lifesciences Holdings Corp (IART) Given Average Rating of "Hold" by BrokeragesIntegra Lifesciences Holdings Corp (IART) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 1:53 PM
Integra Lifesciences (IART) Raised to Buy at BidaskClubIntegra Lifesciences (IART) Raised to Buy at BidaskClub
www.americanbankingnews.com - March 23 at 7:56 PM
Pre-Market Technical Scan on Medical Supplies Equities -- Insulet, Integra LifeSciences, Mazor Robotics, and Microbot MedicalPre-Market Technical Scan on Medical Supplies Equities -- Insulet, Integra LifeSciences, Mazor Robotics, and Microbot Medical
www.bizjournals.com - March 23 at 8:42 AM
Oppenheimer Reaffirms Buy Rating for Integra Lifesciences (IART)Oppenheimer Reaffirms Buy Rating for Integra Lifesciences (IART)
www.americanbankingnews.com - March 22 at 4:08 PM
Why Does Dentsply Sirona Expect Its Earnings Margins to Be under Pressure in 2018?Why Does Dentsply Sirona Expect Its Earnings Margins to Be under Pressure in 2018?
finance.yahoo.com - March 21 at 5:22 PM
Integra Lifesciences (IART) Upgraded to "Hold" by BidaskClubIntegra Lifesciences (IART) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - March 17 at 5:36 PM
Integra Lifesciences Holdings Corp (IART) VP Sells $491,940.90 in StockIntegra Lifesciences Holdings Corp (IART) VP Sells $491,940.90 in Stock
www.americanbankingnews.com - March 15 at 7:46 PM
Reading Dentsply Sirona’s Recent Stock PerformanceReading Dentsply Sirona’s Recent Stock Performance
finance.yahoo.com - March 15 at 5:48 PM
$349.68 Million in Sales Expected for Integra Lifesciences Holdings Corp (IART) This Quarter$349.68 Million in Sales Expected for Integra Lifesciences Holdings Corp (IART) This Quarter
www.americanbankingnews.com - March 14 at 5:15 PM
Integra Lifesciences Holdings Corp (IART) VP Sells $368,084.00 in StockIntegra Lifesciences Holdings Corp (IART) VP Sells $368,084.00 in Stock
www.americanbankingnews.com - March 12 at 7:38 PM

SEC Filings

Integra lifesciences (NASDAQ:IART) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Integra lifesciences (NASDAQ:IART) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Integra lifesciences (NASDAQ IART) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.